Our Mission
To transform influenza prevention and reduce its global health burden by developing vaccines designed to provide broader and longer‑lasting protection, starting with OVX836 and extending this approach over time through collaborations to other infectious diseases.
Our Story
Osivax was born from a simple question the vaccine industry had not yet answered: what if, instead of chasing a constantly mutating virus, you could target the part that cannot change?
Founded in Lyon in 2017, Osivax has spent the past several years building clinical evidence to demonstrate that broader and more durable protection against influenza is achievable. Originating from research co‑developed with the University of Oxford and supported by the Gates Foundation, the company has advanced its lead program from preclinical development to a Phase 2b clinical trial, enrolling more than 4,000 participants. Osivax owns all intellectual property related to its technology and vaccine candidates and has secured the freedom to operate required to support their development and commercialization.
Behind every milestone stands the same core team of scientists, clinicians, and operators who have been building Osivax’s scientific and clinical journey from the very beginning.
Our Values
Team Spirit
We believe that the best science happens when diverse expertise comes together. Collaboration across functions, sites, and partners is how we move faster and further.
Integrity
We hold ourselves to the highest standards of scientific and ethical conduct. Transparency with our partners, investors, and clinical trial participants is non-negotiable.
Agility
In a fast-moving field, the ability to adapt, iterate, and respond to new data is a competitive advantage. We stay nimble without compromising rigour.
Excellence
From preclinical design to Phase 2b execution, we pursue quality at every stage. Excellence is not a milestone. It is how we operate.
What We Do
A differentiated Platform
Our oligoDOM™ technology activates both T-cell and B-cell immunity, enabling protection against conserved, internal viral structures that do not mutate.
A validated pipeline
Three vaccine candidates are currently advancing in clinical development. Our lead program, OVX836, has reached Phase 2b.
A global ambition
Backed by BARDA, Wellcome Trust, and Meiji Seika Pharma, Osivax is building the evidence base to make universal vaccines a clinical reality.
Our Team
Alexandre Le Vert
Executive Chairman & Co-FounderAlexandre has more than 20 years of experience in healthcare ranging from research and development to commercialization of vaccines and therapeutics
He is an experienced entrepreneur in biotech and innovation
Alexandre is a Board Member of several biotech companies in France and in the US
Prior experience:
• CEO, IMAXIO (2011-2017)
• Investment Director, Pradeyrol Développement (2011-2014)
• Consultant, Boston Consulting Group (2009-2011)
• Marketing Manager and Sales Director, BMS France (2003-2008)
• Research scientist, Harvard University and Institut Pasteur (2001-2003)
• 2nd Lieutenant, 1er RPIMa, French Special Forces (1999-2000)
Education:
• Ecole Polytechnique (MS), Palaiseau, France
• Harvard University, MA, USA
Alexandre Le Vert
Executive Chairman & Co-Founder
Dr Florence Nicolas, PhD
Chief Scientific Officer & Co-FounderFlorence has more than 25 years of experience in the development of biological products, vaccines and delivery systems, in particular in the areas of CMC, pharmacology, preclinical studies and preparation of regulatory documents for clinical trial application. Florence is also the Head of the influenza vaccine program.
She also holds extensive experience in project and team management
Prior experience:
• Director of Preclinical Development, IMAXIO (2015-2017)
• Head of Preclinical and Bioanalysis Department, Flamel Technologies (2006-2015)
• Preclinical and clinical stage Project’s leader, Flamel Technologies (2006-2010)
• Research engineer, chemical, preclinical and clinical departments, Flamel Technologies (1995-2006)
Education:
• PhD of Medical Biology, Institut National des Sciences Appliquées, Lyon
• Biochemistry engineer, Institut National des Sciences Appliquées, Lyon
Dr Florence Nicolas, PhD
Chief Scientific Officer & Co-Founder
Dr Nicola Groth, MD
Chief Medical OfficerNicola has 25 years of experience in vaccine development with considerable expertise in influenza vaccines. Through her various strategic positions in the industry, she has developed expertise throughout the vaccine lifecycle, including close and extensive interactions with regulatory agencies.
Prior Experience:
• Global Head of Safety Evaluation & Risk Management, GlaxoSmithKline (GSK) Vaccines, Siena (2015-2023)
• Global Head Clinical Trial Serious Adverse Event Management, Novartis Vaccines and Diagnostics, Siena (2013-2015)
• Senior Epidemiologist, Novartis Vaccines and Diagnostics, Siena (2010-2013)
• Global Lead Influenza Vaccines, Medical Affairs, Novartis Vaccines and Diagnostics, Siena (2009-2010)
• Global Head Clinical Influenza Vaccine Development, Novartis Vaccines and Diagnostics, Siena (2006-2009)
• Clinical Team Leader, Chiron Corporation, Siena (2003-2006)
• Medical Monitor, Clinical Research and Development, Chiron Corporation, Siena (2001-2002)
Education:
• Doctor of Medicine from Siena University
• PhD in Hygiene and Preventive Medicine from Siena University
Dr Nicola Groth, MD
Chief Medical Officer
Dr. Delphine Guyon-Gellin, DVM
Chief Business Officer & Chief Operating OfficerDelphine has 15 years experience in vaccines business and strategy working as strategic consultant for leading pharmaceutical companies to help them solve their key challenges, along with an in-depth expertise in strategy for vaccines
Prior experience:
• Project leader, Boston Consulting Group, London (2014-2017)
• Senior Consultant, Boston Consulting Group, Paris (2011-2014)
• Junior Consultant, AEC Partners, Paris (2007-2011)
Education:
• Doctor of Veterinary Medicine, Ecole Vétérinaire de Maisons-Alfort
• Master’s Degree, HEC, Paris
Dr. Delphine Guyon-Gellin, DVM
Chief Business Officer & Chief Operating Officer
Linda Lebon
Chief Regulatory OfficerLinda has more than 25 years of experience in developing and implementing regulatory strategy for EU and US for different types of products including biotech and various therapeutic area.
Her knowledge of drug development and regulatory matters is enhanced by her understanding of the challenges with which pharmaceutical companies are confronted in their effort to bring a promising drug candidate from the preclinical stage to clinical phases.
Prior experience:
• Lebon Regulatory Science Strategy: Founder & Managing Director (2012-present)
• Argenx: Vice president Regulatory Affairs (2016-2018)
• BMS: Director Regulatory Science, Oncology. Life Cycle management for registered products (2011)
• Voisin consulting Life Science: Project Director-Senior Director (2008-2011)
• Quintiles Transnational (now IQVIA): Senior Manager – Associate Director- Director Regulatory Affairs (2000-2008)
• GSK Vaccine registration manager for Europe. Coordination for submission of registration dossiers at national level as well as EU, mutual recognition and EMA (1996-1999)
• PFIZER Animal Health (previously SmithKline Beecham Animal Health): Regulatory Affairs Associate-Manager for animal health vaccines (1995-1996)
Education:
• HEC School of Management, Liège, Belgium – MBA
• University of Liège-Sciences aggregation with high honors
• University of Liège- Master in Biological sciences (Molecular and cellular biology) with high honors
Linda Lebon
Chief Regulatory Officer
Vincent Monchois
Chief Manufacturing OfficerVincent has over 20 years of experience in bioprocess development and manufacturing, with deep expertise spanning recombinant proteins, monoclonal antibodies, vaccines and gene therapies. He has held senior leadership roles in biotech and CDMO environments, where he managed cross-functional teams, led large-scale CMC programs from early discovery to late-stage clinical supply, and supported global regulatory filings.
Prior experience:
- CMC Director, Vivet Therapeutics (2021–2025)
- Associate Director, Biotech Process Sciences, Merck Group (2017–2021)
- Strategic Project Director & R&D Director, Novasep Biopharma Business Unit (2010–2019)
- Director of Development & Production, PX’Therapeutics (2009–2010)
- Director of Technological Development, PX’Therapeutics (2003–2008)
- Project Development Manager, PX’Therapeutics (2002–2003)
- Project Manager, CNRS-AVENTIS (2000–2002)
- Research Associate, Newcastle University (1998–1999)
Education:
- PhD in Molecular and Cellular Biology & Genetics, INSA Toulouse
- Master’s Degree, INSA Toulouse
Vincent Monchois
Chief Manufacturing Officer
Florian Sourd
VP FinanceFlorian has over 10 years of experience in corporate finance and financial services. Florian was involved more specifically in healthcare transactions for diagnostic companies and healthcare provider group.
Prior experience:
• Manager in Transaction Services, Deloitte (2015-2019)
• Chief Financial Officer, OnyxT+ (2014-2015)
• Senior in Financial Audit, EY (2012-2014)
• M&A Analyst, BNP Paribas CIB (2011)
Education:
• MSc in Management, EMLYON Business School, Lyon, France
• Corporate Finance, RSM, Rotterdam, the Netherlands
Florian Sourd
VP Finance
Marianne Duparc
Head of HR and CommMarianne has broad experience in the life sciences sector, having worked across biotechnology and biopharmaceuticals companies. She has built a transversal career spanning quality assurance, operational excellence, corporate communication, investor relations and human resources. This combination enables her to connect scientific, regulatory, and strategic dimensions to support organizational growth and transformation.
Prior experience:
• Corporate Communication and Investor Relations Manager, Osivax (2022–2025)
• Communication Manager, Erytech Pharma (2021–2022)
• Program Manager, Erytech Pharma (2019–2021)
• Operational Excellence manager, Erytech Pharma (2017–2018)
• Quality Assurance Manager, Sanofi Pasteur MSD (2015–2016)
• Deputy Head of Quality, Novasep (2014–2015)
• Head of Quality, Centre de Bioproduction de Genopole (2011–2013)
• Quality engineer, PX’Therapeutics (2008–2011)
• Regulatory Affairs Associate, Sanofi Aventis (2007–2008)
Education:
• Master’s Degree in Quality, Université Blaise Pascal, Clermont-Ferrand
• Master’s Degree in Biotechnology, University of Montpellier
Marianne Duparc
Head of HR and Comm
Charlotte Primard
Head of Non-Clinical ImmunologyCharlotte has nearly 20 years of experience in non-clinical vaccine development, with expertise in immunology, vaccine mechanism of action, and preclinical evaluation of efficacy and safety. At Osivax, she leads outsourced preclinical activities, and supports vaccine programs by fostering strong cross-functional collaborations with teams in analytics, formulation, and immunology.
Prior Experience:
• Preclinical Studies – Project Manager, Osivax, Lyon (2021-2025)
• Operational Manager & R&D Leader, Adjuvatis, Lyon (2014–2021)
• Project Leader, CNRS – Centre National de la Recherche Scientifique, Lyon (2011–2014)
• Postdoctoral Scientist, University of Geneva, Switzerland (2010–2011)
Education:
• PhD in Pharmaceutical Sciences, Université Jean Monnet, Saint-Etienne
• Master’s Degree in Biotechnology, University of Limoges
Charlotte Primard
Head of Non-Clinical Immunology
Prof. Jeffrey Almond, PhD
Chairman of the Scientific Advisory BoardProf. Jeffrey Almond is a pre-eminent vaccinologist. He has more than 40 years of expertise in the field of vaccines and Influenza
Expertise:
• His scientific contributions include the first demonstration that a single gene can determine host range – a finding highly relevant to understanding evolution of new Influenza pandemic strains
• Completion of the genetic map of an avian influenza virus
• First detailed description of the proteins of Influenza B virus
• Major contributions to the understanding of polio virus and its vaccines
Prior experience:
• Consultant and Scientific Advisory, multiple SABs public sector and Biotech companies (2016-present)
• Visiting Professor, University of Oxford and University of Reading, UK (2016-present)
• VP and Head of Discovery Research and External R&D, Sanofi Pasteur (1999-2013)
• Professor, University of Reading, UK (1985-1999)
• Lecturer, University of Leicester (1979-1985)
Award:
• Oxford Martin Fellow with the Oxford Martin Programme on Vaccines
• Elected Fellow of the American Academy of Microbiology
• Fellow of the UK Academy of Medical Sciences
• Ivanovsky Medal, Scientific Council of Virology, Russian Academy of Medical Sciences (1999)
• Fleming Award (1985)
Education:
• PhD of Philosophy, Virology, University of Cambridge, UK (1974-1976)
• BSc, Microbiology and Biochemistry combined honours, University of Leeds, UK (1969-1973)
Prof. Jeffrey Almond, PhD
Chairman of the Scientific Advisory Board
Dr Nathalie Garcon, Pharm D, PhD
Member of the Scientific Advisory BoardDr. Nathalie Garçon has more than 30 years of expertise in vaccinology, from research to manufacturing, in particular immunology, adjuvant and formulation technologies
Expertise:
• 5 new innovation projects selected, with implementation path defined and milestone established for go/no go decision
• Restructuration of North America RD, with downsizing from 4 to 2 sites, and successful integration within the global RD
• Defined and implemented strategy linked to the adjuvant part of first adjuvanted HPV vaccine registration worldwilde
• Streamlined the group organization, put in place processes to optimize the output and define programs supporting the vaccine projects
• Development of adjuvants processes to be compatible with large scale manufacturing. Set up internal process for preclinical experiment tracking and reporting
• Developed pilot plan processes for adjuvant systems to be used for first time in human clinical trials material
Prior experience:
• CEO/CSO, BioAster (2014-present)
• VP and Head of global adjuvant centre for vaccine development at GSK, Belgium (2012-2014)
• VP, Head of global vaccine centre for adjuvants and technology innovation, GSK, Belgium (2012-2014)
• VP global center for adjuvants and delivery systems, GSK, Belgium (2009-2012)
• VP, Head of research and North America R&D, GSK, Belgium/Canada/USA (2008-2009)
• Director Research and new technologies R&D, GSK, Belgium (2005-2008)
• Director alternative deliveries and preclinical operations, GSK, Belgium (2004-2004)
• Director formulation technology platform, GSK, Belgium, (1990-2003)
• Research associate professor, Baylor College of Medicine, Houston, Texas (1987-1990)
• Postdoctoral research fellow, Royal Free Hospital, London, UK (1986)
Award:
• S. Plotkin award for life time contribution in vaccines and vaccine technologies (2014)
• Author of over 60 papers and book chapters
• Holder of more than 100 patents
Education:
• PhD in biological pharmacy
• PhD in immunotoxicology and immunopharmacology (1982-1985)
• PharmD, Université Claude Bernard, Lyon (1982-1984)
Dr Nathalie Garcon, Pharm D, PhD
Member of the Scientific Advisory Board
Dr Fergal Hill, MD
In Memoriam: Co-founder and visionary leader, Fergal passed away in April 2024. His legacy and impact continue to inspire us every day.Dr. Fergal HILL is co-inventor of the pro-immunogenic tags oligoDOM® (OVX313) in its first and second generation. He has published in prominent international journals and is the coauthor of more than 15 patents or patent applications.
Prior experience:
• CSO, IMAXIO (2000-2017)
• Researcher, European Molecular Biology Laboratory, Heidelberg, Germany (1999-2000)
• Researcher, Laboratory of Molecular Biology, Cambridge, UK (1991-1998)
Education:
• BA, Universities of Oxford, UK
• MB, B. Chir, University of Cambridge, UK
Dr Fergal Hill, MD
In Memoriam: Co-founder and visionary leader, Fergal passed away in April 2024. His legacy and impact continue to inspire us every day.
Dr. Tim Mosmann
Member of the Scientific Advisory BoardDr. Tim Mosmann is Director of the human immunology center at the University of Rochester, with more than 40 years of experience and major contributions in T cell mediated immunity
Expertise
• Established a high-throughput proliferation and cytotoxicity assay for cytokines
• Used this assay to show that there were discrete patterns of cytokines produced by different T cell lines. This work expanded into the characterization of different functions and further cytokine patterns of Th1 and Th2 T cells
• Demonstrated that effector T cells were specialized for different functions, and laid the groundwork for more recent demonstrations of additional stable or semi-stable T cell subsets
• Led to the prediction of a cross-regulatory cytokine, resulting in the discovery of IL-10
• Worked on a subset of uncommitted precursor T memory cells that constitute a surprisingly large proportion of many human immune responses
• Is working on the objective analysis of flow cytometry data, collaborating on the development of algorithms that allow objective mining of the rich information contained in flow cytometry datasets
Prior Experience:
• Director of the Human Immunology Center, University of Rochester, USA (1998-present)
• Professor and Chair, Department of Immunology, University of Alberta, Canada (1990-1998)
• Research Scientist, DNAX then acquired by Schering plough, Palo Alto, USA (1982-1990)
• Assistant Professor, University of Alberta (1977-1982)
• Post-doctoral fellow, University of Glasgow (1975-1977)
• Post-doctoral fellow, Hospital for Sick Children, University of Toronto (1973-1975)
Awards:
• Novartis Prize for Basic Immunology, 2013
• Pillar of Immunology, 2005, 2012, 2016
• Paul Ehrlich and Ludwig Darmstaedter Prize, 2008
• ASTECH award for Outstanding Leadership in Alberta Science, 1997
• William B. Coley Award, Cancer Research Institute (USA), 1997
• Fellow of the Royal Society of Canada, 1995
Education:
• Ph.D., microbiology, University of British Columbia, Canada (1973)
• BSc, microbiology, Rhodes University, USA (1969)
• BS, Chemistry and physiology, University of Natal, South Africa (1968)
Dr. Tim Mosmann
Member of the Scientific Advisory Board
Prof. Geert Leroux-Roels, MD, PhD
Member of the clinical Advisory BoardProf. Geert Leroux-Roels is an Emeritus professor of Ghent University, Faculty of Medicine & Health Science, founder and former director of the Center for Vaccinology (CEVAC) at Ghent University and University Hospital. He acts as a private consultant and keeps supporting CEVAC activities as clinical investigator and scientific advisor.
Expertise:
• Conducted more than 250 clinical vaccine studies at the Center for Vaccinology
• Supported the development of numerous vaccines among which vaccines against HBV, HCV, HIV, malaria, tuberculosis, pandemic influenza.
• Supported the development of novel adjuvants and adjuvant systems and studied the immunobiology of their actions
• Developed small animal models to study infections with HIV and hepatotropic viruses
Prior Experience:
• Professor Emeritus at Ghent University, Belgium (2017-Present)
• Founder and Director of the center for vaccinology, Belgium (1990-2017)
• Professor at Ghent University, Belgium (1976-2017)
Award:
• Member of the Belgian Royal Academy
• Sabin Prize for Vaccine Research (Laureate 1995-1996)
• Special Fellow of the Leukemia Society of America Inc. (1983-1985)
• Fogarty International Research Fellowship Award of the National Institutes of Health (NIH) (1981-1983)
Education:
• “Habilitation” in Clinical Pathology and Immunology, Ghent University, Belgium (1987)
• PhD degree in Biomedical Sciences, Ghent University, Belgium (1981)
• Medical Degree, Ghent University, Belgium (1976)
Prof. Geert Leroux-Roels, MD, PhD
Member of the clinical Advisory Board
Dr Bernard Fritzell, MD
Member of the clinical Advisory BoardDr Bernard Fritzell is an independent consultant with 35 years’ experience in the clinical development of vaccines
Expertise:
• Major Contributions to the understanding of polysaccharide conjugate vaccines including Haemophilus influenza type B, meningococcal group A & C and Streptococcus pneumoniae and associated vaccination strategies
• Contributions to the clinical development of Hepatitis B, rabies and live attenuated Influenza vaccines,
• Established relationship between antibiotic resistance and SP serotypes
Prior experience:
• President of BFL councils, Bordeaux France (2012-present)
• Vice president international scientific and clinical affairs, Wyeth/Pfizer Vaccines, Paris, France (1999-2012)
• Former Chairman of the clinical working group of the European Vaccines Manufacturers (EVM) (1996-2010)
• Vice President, Clinical Research and Medical Affairs, Chiron Vaccines, Siena, Italy (1996-1999)
• Head of clinical research in the medical department of Pasteur-Merieux-Connaught, Paris, France (1993-1996)
• Director Clinical Research, Connaught Laboratories Inc., Swiftwater PA, USA (1991-1993)
• Director Clinical Research, Pasteur-Mérieux Sérums et Vaccins, Marne-la-Coquette, France (1989-1991)
• International Medical Director, Institut Pasteur Production/Pasteur Vaccins, Marne-la-Coquette France (1983- 1989),
• Governmental position at the ministry of health in Somalia (1981-1983)
• Medical Attaché to the French Embassy in Beijing, China (1978-1979)
Education:
• Degree in Statistics applied to Epidemiology and Clinical Research, University Pierre et Marie Curie, Paris VI, France
• Degree in Health and development, University of Bordeaux, France
• Degree in Tropical diseases, University of Bordeaux, France
• Medical Degree, University of Bordeaux, France
Dr Bernard Fritzell, MD
Member of the clinical Advisory Board
Dr W. Ripley Ballou, MD
Member of the clinical Advisory BoardDr W. Ripley Ballou currently serves as Principal Investigator for the ADVANCE Program at IAVI, he also held several leadership positions at GSK Vaccines globally and in the US, and with the Gates Foundation. Rip brings over 30 years of experience in the clinical development of vaccines.
Expertise:
• Experience with multiple clinical development for vaccines against infectious diseases including HIV, CMV, varicella zoster, influenza (seasonal and pandemic), streptococcus, malaria, and tuberculosis
• 30 years of clinical development in international vaccines companies as well as non-profit institutions in both US and Europe
• Deep understanding of U.S and European vaccines approval systems and close relationship with both the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
Prior experience:
• Principal Investigator for the ADVANCE Program, IAVI in Washington D.C, MD (2020-current)
• VP and Head of Global Vaccines at GSK Vaccines R&D Center in Rockville, MD (2015 – 2020)
• VP Global Clinical R&D & Head of Translational Science, GSK Vaccines, Rixensart in Belgium (2010 – 2015)
• Deputy Director for Vaccines, Bill and Melinda Gates Foundation, Department of Infectious Diseases (2008-2009)
• VP Global Clinical R&D, GSK Biologicals, Rixensart in Belgium (2003 – 2008)
• VP Clinical Development in Vaccines & Infectious Diseases, MedImmune (1999-2002)
• Chief, Department of Immunology at the Walter Reed Army Institute of Research in Washington D.C, MD (1990-1999)
Education:
• Medical Degree, Emory University School of Medicine, USA
• Degree in Applied Biology, Georgia Institute of Technology, USA
Dr W. Ripley Ballou, MD
Member of the clinical Advisory Board
Prof. Odile Launay, MD, PhD
Member of the clinical Advisory BoardOdile Launay is Professor of Infectious diseases at the University of Paris. She is the Director of the Clinical Investigation Center in Vaccinology (CIC Cochin Pasteur), the only French clinical investigation center dedicated to vaccinal research based in Paris, since it is creation in 2005 and Coordinator of the French Innovative Clinical Network in Vaccinology (I-REIVAC) in the FCrin Program. She is member of the board of the College of Teacher of Infectious Disease (CMIT).
Expertise:
• Coordinated and conducted more than 50 academic and industrial vaccine trials (phases 1-4)
• Cooperate with public health institutions including Inserm (Institut national de la santé et de la recherche médicale) and the Aviesan Institute of Microbiology and Infectious Diseases, the pasteur Institute and the National Agency for AIDS Research
Prior experience:
• Director of the French clinical Network in vaccinology (2007- present)
• Director of the Clinical Investigation Center in Vaccinology CIC, Paris (2005 – present)
• Infectious disease specialist in Cochin Hospital, Paris (2002-present)
• Vice-chair of the French technical committee on vaccination (CTV) (2007 – 2016)
• Expert at the National Security Agency of Medicines and Health Products (ANSM) (2003-2011)
Education:
• PhD in Experimental and clinical Pharmacology, Paris 5 University (2007)
• Infectious Diseases specialist, Paris 6 University, France (2001)
• Medical degree, Paris 6 University, France (1995)
Prof. Odile Launay, MD, PhD
Member of the clinical Advisory Board
Prof. Pierre Vandamme, MD, PhD
Member of the clinical Advisory BoardProf. Pierre Van Damme is the former Chairman of the Vaccine & Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp, and head of the Centre for the Evaluation of Vaccination with more than 25 years of experience in vaccinology
Expertise:
• Conducted more than 350 vaccine trials at the Center for the Evaluation of Vaccination
• More than 20 years a regular advisor for national and international organizations, including the Flemish Vaccination platform, the National Immunization Technical Advisory Group and the World Health Organization
Prior experience:
• Executive Secretary of the Human Papilloma Virus Control and Prevention Board (2015-present)
• Professor at the University of Antwerp (2000-present)
• Founder of the Center for the Evaluation of Vaccination (1994 – present)
• Executive Secretary of the Viral Hepatitis Prevention Board (1994-present)
• Chairman of the Vaccine & infectious Disease Institute, VAXINFECTIO, University of Antwerp (2008 – 2018)
• Chairman of the European Technical Advisory Group of Experts on communicable diseases and vaccines for WHO European Region (2004-2014)
Award:
• Member of the Belgian Royal Academy of Medicine
• Research Award of the University of Antwerp
• Belgian Social Medicine Award “Jean Van Beneden” for his work on the introduction of universal hepatitis B immunization programs
• Bill Marshall Award of the ESPID society (2014)
Education:
• Master’s degree in occupational health
• Degrees in Health & Economics
• PhD in epidemiology and social medicine, University of Antwerp (1994)
• Medical Degree, University of Antwerp, Belgium (1984)
Prof. Pierre Vandamme, MD, PhD
Member of the clinical Advisory Board
Alexandre Le Vert
Executive Chairman & Co-FounderAlexandre has more than 20 years of experience in healthcare ranging from research and development to commercialization of vaccines and therapeutics
He is an experienced entrepreneur in biotech and innovation
Alexandre is a Board Member of several biotech companies in France and in the US
Prior experience:
• CEO, IMAXIO (2011-2017)
• Investment Director, Pradeyrol Développement (2011-2014)
• Consultant, Boston Consulting Group (2009-2011)
• Marketing Manager and Sales Director, BMS France (2003-2008)
• Research scientist, Harvard University and Institut Pasteur (2001-2003)
• 2nd Lieutenant, 1er RPIMa, French Special Forces (1999-2000)
Education:
• Ecole Polytechnique (MS), Palaiseau, France
• Harvard University, MA, USA
Alexandre Le Vert
Executive Chairman & Co-Founder
Dr Chris Martin, PhD
Chairman of the Board of Tokamak Energy LtdChris has over 20 years of experience in the pharmaceutical and biotech sector. He is an accomplished company founder and Director who has successfully brought technology from the lab to regulatory approval and global markets.
Prior experience:
• Chairman of the Board, Tokamak Energy Ltd (2015-current)
• Co-founder and CEO, ADC Therapeutics (2012 – 2022)
• Non Executive Director, Xenva Ltd (1998 – 2018)
• VP Spirogen, AstraZeneca (2013 – 2015)
• Non Executive Director, Allianz Technology Trust PLC (2004 – 2015)
• Co-founder and CEO, Spirogen Ltd (2000 – 2015)
• Chairman, Crescent Diagnostics (2006 – 2013)
• Co-founder and Chairman, Sciona Inc. (2000 – 2009)
Education:
• MBA from IMD business School
• PhD in Engineering Science from the University of Oxford
• Bachelor’s degree in Chemical Engineering from Aston University
Dr Chris Martin, PhD
Chairman of the Board of Tokamak Energy Ltd
Dr Frédéric Schynts, PhD
Noshaq Investment ManagerFrédéric is a scientist with Virology, Immunology and Vaccinology background, experienced in vaccine, cell and gene therapy development from R&D to clinical phase, Business Development and Company Development strategy. Continuous learning and training on the Managerial and Entrepreneurial aspect of the Biotech Industry.
Prior experience:
• Investment Manager, Noshaq (2020-Present)
• Independent Consultant (Schynts Consulting, 2013-Present)
• Non Clinical Development Expert (EyeD Pharma, 2018-Present)
• Senior Consultant (Rommel Consulting Partners, 2013-Present)
• Project Leader (EKLO, 2013-2020)
• Director Development Intelligence (GSK Vaccines, 2010-2013)
• Project Leader Life Cycle Management of Seasonal Influenza Vaccines (GSK Vaccines, 2009-2010)
• Head of Molecular Analytics (GSK Vaccines, 2007-2009)
• Scientific Director (CER Group, 2005-2007)
• Director of the Virology Department (CER Group, 2002-2005)
Education:
• Master in Laboratory Animal Sciences (ULiège, Belgium, 2003)
• PhD in Veterinary Sciences (Virology, Immunology, and Vaccinology, ULiège Belgium, 2002)
• Visiting Scientist (Virginia Commonwealth University, USA, 2001)
• Doctor In Veterinary Medicine (ULiège, Belgium, 1996)
Dr Frédéric Schynts, PhD
Noshaq Investment Manager
Dr Christian Pradeyrol, MD
Executive Chairman and founder of Pradeyrol DéveloppementDr PRADEYROL is the Executive Chairman and Founder of Pradeyrol Développement, a family office actively investing in new technologies. With participations in a dozen of Biotech companies in France and in the US, Pradeyrol Développement is highly interested in immunology and preventive medicines, in vaccines, drugs and diagnostics.
Prior experience:
• Chairman and CEO, IMAXIO (2018 – current)
• Executive Chairman and founder of Pradeyrol Développement (2007-current)
• Founder and manager of CHP group, a leading French group of private clinics – acquired by Blackstone in 2007
• Anaesthesiologist
Education:
• Medical Degree from the University of Clermont-Ferrand
Dr Christian Pradeyrol, MD
Executive Chairman and founder of Pradeyrol Développement
Dr Thomas Joudinaud, MD
CEO of Ceres-Brain TherapeuticsThomas has broad experience in healthcare ranging from practicing medicine to research, development and commercialization of therapeutics. He is a Cardio-vascular Thoracic surgeon by training and have more than 10 years of strategy consulting experience specialized in healthcare. Today, Thomas is CEO of Ceres-Brain Therapeutics, a biotech company spin-off from the CEA, and specialized in rare cerebral diseases. Thomas was Board Member of the University Paris V René Descartes from 2012 to 2016.
Prior experience:
• CEO, Ceres-Brain Therapeutics (2020 – current)
• Partner, AEC Partners (2016-current)
• Consultant to Principal, Boston Consulting Group (2009-2016)
• Chief Resident, cardiac surgery, Bichat hospital, Paris (2006-2009)
• Research fellow, The International Heart Institute of Montana Foundation, Saint Patrick Hospital, The University of Montana, Montana, USA (PhD thesis director Pr C. Duran)
• Resident in surgery, Paris University Hospital
Education:
• Medical degree from the Paris V University
• The University of Montana, Cardiovascular Science, Pharmacy Department
Dr Thomas Joudinaud, MD
CEO of Ceres-Brain Therapeutics
Frédéric Cren
Member of the Board of DirectorsFrédéric Cren is a biopharmaceutical executive, entrepreneur and co-founder of Inventiva, a clinical-stage biotechnology company listed on Euronext Paris and Nasdaq. He brings over 30 years of international leadership experience in biotech company creation, corporate strategy, financing, business development, R&D leadership and public-market governance. He served as Chief Executive Officer of Inventiva from the company’s inception until 2025, leading its development from a French biotech start-up into a publicly listed clinical-stage company.
Expertise:
• Extensive experience in biotech company creation, executive leadership and corporate strategy
• Strong expertise in business development, financing strategy, investor relations and public-market governance
• Experience leading a dual-listed biotechnology company on Euronext Paris and Nasdaq
• Deep knowledge of drug development, R&D strategy and therapeutic innovation in areas with high unmet medical needs
• Experience building strategic partnerships with pharmaceutical companies, biotech firms and academic institutions
Prior Experience:
• Co-founder, Inventiva, France (2012-2025)
• General Manager, Research, Abbott Laboratories, France (2010-2012)
• Senior roles, Solvay Pharmaceuticals, France (2005-2010)
• Senior roles, Laboratoires Fournier, France (2001-2005)
• Manager, BCG (1992-2001)
Education:
• Master of Business Administration, INSEAD, France (1995)
• Master’s Degree in International Relations, Johns Hopkins University, United States (1990)
• Bachelor’s Degree in Economics, Paris IX Dauphine University, France (1988)
Frédéric Cren
Member of the Board of DirectorsOur Investors
Osivax’ approach and mission are further validated and supported by our trusted investors.
Non-Dilutive Support
Our Partners
